The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
Open accessAbstract
Expression of receptor for hyaluronan-mediated motility (RHAMM), a breast cancer susceptibility gene, is tightly controlled in normal tissues but elevated in many tumors, contributing to tumorigenesis and metastases. However, how the expression of RHAMM is regulated remains elusive. Statins, inhibitors of mevalonate metabolic pathway widely used for hypercholesterolemia, have been found to also have antitumor effects, but little is known of the specific targets and mechanisms. Moreover, Hippo signaling pathway plays crucial roles in organ size control and cancer development, yet its downstream transcriptional targets remain obscure. Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization. Further, modulation by mevalonate/simvastatin of YAP-activated RHAMM transcription requires geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, but is largely independent of MST and LATS kinase activity. These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Elucidation of a universal size-control mechanism in Drosophila and mammals
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., & Pan, D. (2007) · Cell · doi:10.1016/j.cell.2007.07.019 · Cited by 2,370
The Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
Self-citationRegulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205 · cited 10×
“TEAD-mediated transcription is activated upon binding to the transcription coactivator YAP when the latter is not phosphorylated at Ser127 (28, 29).”
BackgroundInfluentialTransforming properties of YAP , a candidate oncogene on the chromosome 11q22 amplicon
Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C.-X., Brugge, J. S., & Haber, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605579103 · Cited by 885
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
Lamar, J. M., Stern, P., Liu, H., Schindler, J. W., Jiang, Z.-G., & Hynes, R. O. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212021109 · Cited by 654
Hippo signaling in organ size control
Pan, D. (2007) · Genes & Development · doi:10.1101/gad.1536007 · Cited by 647
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628
Network modeling links breast cancer susceptibility and centrosome dysfunction
Pujana, M. A., Han, J.-D. J., Starita, L. M., Stevens, K. N., Tewari, M., Ahn, J. S., Rennert, G., Moreno, V., Kirchhoff, T., Gold, B., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.2 · Cited by 618
The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway
Hong, W., & Guan, K.-L. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.05.004 · Cited by 493
Dysregulation of the mevalonate pathway promotes transformation
Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910258107 · Cited by 417
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
The BRCA1/BARD1 Heterodimer Modulates Ran-Dependent Mitotic Spindle Assembly
Joukov, V., Groen, A. C., Prokhorova, T., Gerson, R., White, E., Rodriguez, A., Walter, J. C., & Livingston, D. M. (2006) · Cell · doi:10.1016/j.cell.2006.08.053 · Cited by 280
Hamilton, S. R., Fard, S. F., Paiwand, F. F., Tolg, C., Veiseh, M., Wang, C., McCarthy, J. B., Bissell, M. J., Koropatnick, J., & Turley, E. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702078200 · Cited by 266
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 239
Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?
Maxwell, C. A., McCarthy, J., & Turley, E. (2008) · Journal of Cell Science · doi:10.1242/jcs.022038 · Cited by 230
Maxwell, C. A., Benítez, J., Gómez-Baldó, L., Osorio, A., Bonifaci, N., Fernández-Ramires, R., Costes, S. V., Guinó, E., Chen, H., Evans, G. J. R., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001199 · Cited by 192
Self-citationWang, C., Thor, A. D., Moore, D. H., Zhao, Y., KERSCHMANN, R. L., Stern, R., Watson, P. H., & Turley, E. A. (1998) · PubMed · Cited by 181
Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth
Ghosh-Choudhury, N., Mandal, C. C., Ghosh-Choudhury, N., & Ghosh Choudhury, G. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.12.010 · Cited by 177
Hyaluronate Receptors Mediating Glioma Cell Migration and Proliferation
Akiyama, Y., Jung, S., Salhia, B., Lee, S., Hubbard, S.-L., Taylor, M. D., Mainprize, T. G., Akaishi, K., van Furth, W. R., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012297132047 · Cited by 139
Mandal, C. C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G. G., & Ghosh-Choudhury, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193714 · Cited by 138
Mammalian Hippo pathway: from development to cancer and beyond
Bao, Y., Hata, Y., Ikeda, M., & Withanage, K. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr021 · Cited by 137
Maxwell, C. A., Keats, J. J., Belch, A. R., Pilarski, L. M., & Reiman, T. (2005) · Cancer Research · doi:10.1158/0008-5472.850.65.3 · Cited by 124
Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer
Wang, X., Su, L., & Ou, Q. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.001 · Cited by 120
Tölg, C., Poon, R., Fodde, R., Turley, E. A., & Alman, B. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206811 · Cited by 115
Tölg, C., Hamilton, S. R., Morningstar, L., Zhang, J., Zhang, S., Esguerra, K. V. N., Telmer, P. G., Luyt, L. G., Harrison, R. E., McCarthy, J. B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121491 · Cited by 107
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 104
Li, H., Guo, L., Li, J. W., Liu, N., Qi, R., & Liu, J. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.5.927 · Cited by 92
Assmann, V., Gillett, C., Poulsom, R., Ryder, K., Hart, I. R., & Hanby, A. M. (2001) · The Journal of Pathology · doi:10.1002/path.941 · Cited by 91
Gust, K. M., Hofer, M. D., Perner, S., Kim, R., Chinnaiyan, A. M., Varambally, S., Möller, P., Rinnab, L. J., Rubin, M. A., Greiner, J., et al. (2009) · Neoplasia · doi:10.1593/neo.09694 · Cited by 90
Turley, E., Belch, A., Poppema, S., & Pilarski, L. (1993) · Blood · doi:10.1182/blood.v81.2.446.446 · Cited by 89
Rein, D., Roehrig, K., Schöndorf, T., Lazar, A., Fleisch, M. C., Niederacher, D., Bender, H., & Dall, P. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0415-0 · Cited by 82
Hatano, H., Shigeishi, H., Kudo, Y., Higashikawa, K., Tobiume, K., Takata, T., & Kamata, N. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.176 · Cited by 73
Du, Y. N., Chou, C., Klimstra, D. S., & VARMUS, H. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114022108 · Cited by 67
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216421 · Cited by 64
Lugli, A., Zlobec, I., Günthert, U., Minoo, P., Baker, K., Tornillo, L., Terracciano, L., & Jass, J. R. (2006) · Modern Pathology · doi:10.1038/modpathol.3800648 · Cited by 56
Hill, V. K., Dunwell, T. L., Catchpoole, D. R., Krex, D., Brini, A. T., Griffiths, M., Craddock, C., Maher, E. R., & Latif, F. (2011) · Epigenetics · doi:10.4161/epi.6.3.14404 · Cited by 54
Telmer, P. G., Tölg, C., McCarthy, J. B., & Turley, E. A. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.4.2.14270 · Cited by 54
Cited by
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802
Mechanobiology of YAP and TAZ in physiology and disease
Panciera, T., Azzolin, L., Cordenonsi, M., & Piccolo, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.87 · Cited by 1,461
The Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
“Isoprenyl derivatives, such as farnesyl or geranylgeranyl pyrophosphate (GGPP), are substrates for protein modification and membrane anchorage (131, 132).”
Background
Metadata
- Authors
- Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., Jiang, Y., Sun, S., Zheng, Y., Li, N., & Huang, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-12-23
- Volume
- 111
- Issue
- 1
- Pages
- E89-98
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1977291335
- Cited by
- 316
- References
- 46
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.